跳至主要内容
临床试验/CTRI/2020/03/023865
CTRI/2020/03/023865已完成未知

A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Determine Effects of Synbiotic Test Product on Immune Markers and Gut Health In Elderly Population.

Tata Chemicals Ltd0 个研究点目标入组 199 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
199

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Age: 50 to 65 years (both inclusive) old at the time of consent.
  • 2)Subjects with BMI: In between 18.5 to 27.5 kg/m2.
  • 3)Gender: Male or females (Post menopausal female with history at least one year of amenorrhea).
  • 4)Subjects who are sensitive to weather change, cold, cough, fever, sore throat/throat infection etc. by medical history.
  • 5)Subjects with generally good health conditions, free from any disease condition to affect their dietary intake.
  • 6)Subjects with no known side effect/allergy or intolerance to milk, Probiotic, prebiotic or synbiotics or any similar products/food/food ingredients.
  • 7)Subjects must be able to understand and provide written informed consent to participate in the study.
  • 8)Subjects should be willing and able to follow the study protocol to participate in the study.

排除标准

  • 1)Subjects with current use or use in the past 3 months of antimicrobial or steroidal drugs or any prescription medication.
  • 2)Subjects who are not ready to refrain from taking fermented foods like dosa, idly, butter milk, curd, any other supplements (Prebiotic, probiotic, synbiotics etc.) during this study period as well at least 2 week before enrollment. (Refer attached appendix IV).
  • 3)Subjects who are taking fiber supplement or any micronutrient supplement during this study period as well at least 2 week before enrollment.
  • 4)Subjects with medical conditions affecting immune status (e.g., rheumatoid arthritis, heart failure, hepatitis C, HIV) or taking medicine which may have impacts on immune system like antibiotics, antimicrobial, probiotic sachets.
  • 5)Subjects with known history of Diabetes (any form) or any other disease condition which affect their daily dietary intake.
  • 6)History of drug and alcohol abuse.
  • 7)Participation in a similar clinical study within the previous 90 days.
  • 8)Any surgical treatment previous three months or planned during the study.
  • 9)Any subject in the Principal investigators opinion not considered suitable for enrollment.

研究者

相似试验

已完成
3 期
A clinical trial to study the effect of Apremilast Tablets in the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
CTRI/2016/10/007345Glenmark Pharmaceuticals Ltd
进行中(未招募)
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 16.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2010-022576-30-CZRadius Health, Inc.2,400
进行中(未招募)
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2010-022576-30-LTRadius Health, Inc.2,400
进行中(未招募)
1 期
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2010-022576-30-DKRadius Health, Inc.2,400
进行中(未招募)
不适用
A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of FractureOsteoporosis in postmenopausal womenMedDRA version: 17.0Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2010-022576-30-PLRadius Health, Inc.2,400